Companies · Other Health Care
LAFAYETTE · Other Health Care
Diligence memoA one-page analyst read on Onex TSG/HPP Holdings Corp. — recommendation, valuation, rhythm, risks.→Onex TSG/HPP Holdings Corp. looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Onex TSG/HPP Holdings Corp. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Onex TSG/HPP Holdings Corp. is one of 5377 Other Health Care companies tracked from LAFAYETTE. By capital raised it ranks among the largest (ahead of 97% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 17%.
Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 97% of sector peers (real $). Modeled value above 66% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #14 of 16.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Onex TSG Holdings Corp. | Series D+ | $336.0M | $7.7B | 2.94× |
| BVO Holdings, LLC | Series D+ | $335.8M | $7.7B | 2.94× |
| Mdp Hc Holdings, Llc | Series D+ | $310.1M | $7.1B | 2.71× |
| Amsurg Corp | Series D+ | $270.9M | $6.2B | 2.37× |
| Greatbatch, Inc. | Series D+ | $247.2M | $5.7B | 2.16× |
| Hc Group Holdings Iii, Inc. | Series D+ | $144.3M | $3.3B | 1.26× |
| Diplomat Pharmacy, Inc. | Series D+ | $140.0M | $3.2B | 1.23× |
| Proteus Biomedical Inc | Series D+ | $162.4M | $2.7B | 1.05× |
| Mmi Holdings Inc | Series D+ | $109.0M | $2.5B | 0.95× |
| Evolent Health LLC | Series D+ | $221.3M | $2.3B | 0.89× |
| BioScrip, Inc. | Series D+ | $172.5M | $1.4B | 0.55× |
| Envision Rx Options Holdings, Inc. | Series D+ | $144.5M | $80.0M | 0.03× |
| Onex TSG/HPP Holdings Corp. this company | Series D+ | $117.1M | $46.0M | 0.02× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series D+ | $115.1M | 2015-08-24 | $959.2M | $2.6B | 90% |
| Series D+ | $2.0M | 2015-11-13 | $16.7M | $46.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| THOMAS C. DOLAN | — | 3 other | 2015-08 |
| Christopher C. Cotteleer | — | 1 other | 2015-08 |
| Joseph A. Trunfio | — | 1 other | 2015-11 |
| Joshua C. Hausman | — | 1 other | 2015-08 |
| Lee C. White | — | 1 other | 2015-08 |
| Richard C. D'Amaro | — | 1 other | 2015-08 |
| Robert C. Le Blanc | — | 1 other | 2015-08 |
| Ryan C. Domengeaux | — | 1 other | 2015-08 |
| William C. Schumacher | — | 1 other | 2015-08 |
| Charlene S. Frizzera | — | — | 2015-11 |
| Jim S. Kelly | — | — | 2015-11 |
| Mark S. Demilio | — | — | 2015-11 |
Onex TSG/HPP Holdings Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Onex TSG Holdings Corp. | Other Health Care | Series D+ | $336.0M | $7.7B | network8 shared operators · same sector · same stage |
| ArcherDX, Inc. | Other Health Care | Series C | $115.1M | $35.6M | same sector |
| Metabolon, Inc | Other Health Care | Series B | $123.6M | $42.1M | same sector |
| Specialists On Call, Inc. | Other Health Care | Series B | $131.7M | $44.3M | same sector |
| Transenterix Inc | Other Health Care | Series C | $72.2M | $45.7M | same sector |
| Miach Orthopaedics Inc. | Other Health Care | Series C | $67.8M | $44.0M | same sector |
| AccuVein Inc. | Other Health Care | Series B | $64.0M | $53.5M | same sector |
| PrognomIQ, Inc. | Other Health Care | Series B | $56.2M | $49.0M | same sector |
See where Onex TSG/HPP Holdings Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Onex TSG/HPP Holdings Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.